McKesson Corporation MCK

NYSE · Healthcare · Medical - Distribution

$1,069.43

Close on Fri, 20 Nov 2026 · market value $123B

What the price is betting on

Below its record

At $1,069, the price assumes revenue shrinks about 4% a year for five years, from $419B to about $348B by FY2031. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−4%
Analysts, next two years7.1%
Last 3 years13%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.6% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than MCK? Check up to 5 of your stocks at once, free, no account.

0$200B$400B$600B$419B'23'24'25'26Sep '26'27'28'29'30'31What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$1,713

Base

$2,001

Bull

$2,335

Today $1,069

  • Bear $1,713. Cash flow grows 4% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $2,001. Cash flow grows 7% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $2,335. Cash flow grows 9% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2027$410B$435B, on the path
  3. FY2028$394B$465B, on the path
  4. FY2029$378B$496B, on the path
  5. FY2030$363B$522B, on the path
  6. FY2031$348B$570B, on the path

Each year's revenue at −4% growth from $419B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Distribution · listed on NYSE

Revenue, FY2026
$403B
Growth, 3 years a year
13%
Cash margin
1.3%
Net debt
$4.6B
Shares, 3-year change
−13%
Dividend yield
0.3%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.